|
1
|
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho
BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK,
Bondarenko I, et al: Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or
metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised,
open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
Non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang J, Lu S, Yu XM, Hu YP, Sun YP, Wang
ZJ, Zhao J, Yu Y, Hu CH, Yang K, et al: Tislelizumab plus
chemotherapy vs chemotherapy alone as first-line treatment for
advanced squamous Non-small-cell lung cancer: A phase 3 randomized
clinical trial. JAMA Oncol. 7:709–717. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Horn L, Mansfield AS, Szczęsna A, Havel L,
Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio
M, et al: First-line atezolizumab plus chemotherapy in
Extensive-stage Small-cell lung cancer. N Engl J Med.
379:2220–2229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cohen EEW, Soulières D, Tourneau CL, Dinis
J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, et al:
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for
recurrent or metastatic head-and-neck squamous cell carcinoma
(KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet.
393:156–167. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burtness B, Harrington KJ, Greil R,
Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane
P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy
versus cetuximab with chemotherapy for recurrent or metastatic
squamous cell carcinoma of the head and neck (KEYNOTE-048): A
randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun JM, Shen L, Shah MA, Enzinger P,
Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, et al:
Pembrolizumab plus chemotherapy versus chemotherapy alone for
first-line treatment of advanced oesophageal cancer (KEYNOTE-590):
A randomised, placebo-controlled, phase 3 study. Lancet.
398:759–771. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Powles T, Plimack ER, Soulières D, Waddell
T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko
I, et al: Pembrolizumab plus axitinib versus sunitinib monotherapy
as first-line treatment of advanced renal cell carcinoma
(KEYNOTE-426): Extended follow-up from a randomised, open-label,
phase 3 trial. Lancet Oncol. 21:1563–1573. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu YL, Lu S, Cheng Y, Zhou CC, Wang J, Mok
T, Zhang L, Tu HY, Wu L, Feng J, et al: Nivolumab Versus Docetaxel
in a Predominantly Chinese Patient Population With Previously
Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical
Trial. J Thorac Oncol. 14:867–875. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, Pawel JV, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shitara K, Özgüroğlu M, Bang YJ,
Bartolomeo MD, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic
C, Chung HC, et al: Pembrolizumab versus paclitaxel for previously
treated, advanced gastric or gastro-oesophageal junction cancer
(KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial.
Lancet. 392:123–133. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Palumbo JS and Degen JL: Mechanisms
coupling the hemostatic system to colitis-associated cancer. Thromb
Res. 125 (Suppl 2):S39–S43. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang F, Wang Y, Sun P, Wang ZQ, Wang DS,
Zhang DS, Wang FH, Fu JH, Xu RH and Li YH: Fibrinogen promotes
malignant biological tumor behavior involving epithelial
mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal
squamous cell carcinoma. J Cancer Res Clin Oncol. 143:2413–2424.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Steinbrecher KA, Horowitz NA, Blevins EA,
Barney KA, Shaw MA, Harmel-Laws E, Finkelman FD, Flick MJ,
Pinkerton MD, Talmage KE, et al: Colitis associated cancer is
dependent on the interplay between the hemostatic and inflammatory
systems and supported by integrin alpha(M)beta(2) engagement of
fibrinogen. Cancer Res. 70:2634–43. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wen J, Yang Y, Ye F, Huang X, Li S, Wang Q
and Xie X: The preoperative plasma fibrinogen level is an
independent prognostic factor for overall survival of breast cancer
patients who underwent surgical treatment. Breast. 24:745–50. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ohara S, Suda K, Tomizawa K, Takemoto T,
Fujino T, Hamada A, Koga T, Nishino M, Chiba M, Sato K, et al:
Prognostic value of plasma fibrinogen and d-dimer levels in
patients with surgically resected non-small cell lung cancer. Surg
Today. 50:1427–1433. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun Y, Han W, Song Y, Gao P, Yang Y, Yu D,
Wang Y and Wang Z: Prognostic value of preoperative fibrinogen for
predicting clinical outcome in patients with nonmetastatic
colorectal cancer. Cancer Manag Res. 12:13301–13309. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin Y, Liu ZH, Qiu YF, Wu HN, Liang R,
Chen GY, Qin G, Li YQ and Zou DH: Clinical significance of plasma
D-dimer and fibrinogen in digestive cancer: A systematic review and
meta-analysis. Eur J Surg Oncol. 44:1494–1503. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuan CL, Huang MF, Wang HL, Jiang W, Su CY
and Zhou SZ: Pretreatment Fibrinogen-Albumin Ratio (FAR) associated
with treatment response and survival in advanced Non-small cell
lung cancer patients treated with first-line Anti-PD-1 therapy plus
Platinum-based combination chemotherapy. Cancer Manag Res.
14:377–386. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo ZW and Liang J: Fibrinogen-Albumin
Ratio Index (FARI) as a certain prognostic biomarker in pretreated
patients with immunotherapy. Cancer Manag Res. 13:4169–4180. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The Eighth Edition AJCC Cancer Staging Manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen YJ, Wang HG, Wei JY and Li WD: Early
prediction of objective response of fibrinogen in a real-world
cohort of hepatocellular carcinoma cases treated by programmed cell
death receptor-1 and lenvatinib. Onco Targets Ther. 14:5019–5026.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nenclares P, Gunn L, Soliman H, Bover M,
Trinh A, Leslie I, Wong KH, Melcher A, Newbold K, Nutting CM, et
al: On-treatment immune prognostic score for patients with relapsed
and/or metastatic head and neck squamous cell carcinoma treated
with immunotherapy. J Immunother Cancer. 9:e0027182021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mei Y, Zhao S, Lu XF, Liu HX, Li XY and Ma
R: Clinical and prognostic significance of preoperative plasma
fibrinogen levels in patients with operable breast cancer. PLoS
One. 11:e01462332016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Goad KE and Gralnick HR: Coagulation
disorders in cancer. Hematol Oncol Clin North Am. 10:457–484. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Falanga A, Marchetti M and Vignoli A:
Coagulation and cancer: Biological and clinical aspects. J Thromb
Haemost. 11:223–233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Martino MM, Briquez PS, Ranga A, Lutolf MP
and Hubbell JA: Heparin-binding domain of fibrin(ogen) binds growth
factors and promotes tissue repair when incorporated within a
synthetic matrix. Proc Natl Acad Sci USA. 110:4563–4568. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sahni A, Simpson-Haidaris PJ, Sahni SK,
Vaday GG and Francis CW: Fibrinogen synthesized by cancer cells
augments the proliferative effect of fibroblast growth factor-2
(FGF-2). J Thromb Haemost. 6:176–183. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Derynck R, Turley SJ and Akhurst RJ: TGFβ
biology in cancer progression and immunotherapy. Nat Rev Clin
Oncol. 18:9–34. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tennent GA, Brennan SO, Stangou AJ,
O'Grady J, Hawkins PN and Pepys MB: Human plasma fibrinogen is
synthesized in the liver. Blood. 109:1971–194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Falanga A and Marchetti M: Hemostatic
biomarkers in cancer progression. Thromb Res. 164:54–61. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Simpson-Haidaris PJ and Rybarczyk B:
Tumors and fibrinogen: The role of fibrinogen as an extracellular
matrix protein. Ann N Y Acad Sci. 936:406–425. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: Biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zheng S, Shen J, Jiao Y, Liu Y, Zhang CM,
Wei M, Hao S and Zeng XL: Platelets and fibrinogen facilitate each
other in protecting tumor cells from natural killer cytotoxicity.
Cancer Sci. 100:859–65. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shu YJ, Weng H, Bao RF, Wu XS, Ding Q, Cao
Y, Wang XA, Zhang F, Xiang SS, Li HF, et al: Clinical and
prognostic significance of preoperative plasma hyperfibrinogenemia
in gallbladder cancer patients following surgical resection: A
retrospective and in vitro study. BMC Cancer. 14:5662014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang N, Ng AS, Cai S, Li Q, Yang L and
Kerr D: Novel therapeutic strategies: Targeting
epithelial-mesenchymal transition in colorectal cancer. Lancet
Oncol. 22:e358–e368. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yamamoto T, Gotoh M, Sasaki H, Terada M,
Kitajima M and Hirohashi S: Molecular cloning and initial
characterization of a novel fibrinogen-related gene, HFREP-1.
Biochem Biophys Res Commun. 193:681–687. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang J, Sanmamed MF, Datar I, Su TT, Ji L,
Sun J, Chen L, Chen Y, Zhu G, Yin W, et al: Fibrinogen-like Protein
1 is a major immune inhibitory ligand of LAG-3. Cell. 176:334–347.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Izuegbuna OO, Agodirin OS, Olawumi HO and
Olatoke SA: Plasma D-Dimer and fibrinogen levels correlates with
tumor size and disease progression in nigerian breast cancer
patients. Cancer Invest. 39:597–606. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang H, Gao JB, Bai M, Liu R, Li H, Deng
T, Zhou L, Han R, Ge S, Huang D and Ba Y: The pretreatment platelet
and plasma fibrinogen level correlate with tumor progression and
metastasis in patients with pancreatic cancer. Platelets.
25:382–387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada
A, Oishi T, Isobe Y, Kubochi K, Kitajima M and Matsumoto S:
Pretreatment plasma fibrinogen level correlates with tumor
progression and metastasis in patients with squamous cell carcinoma
of the esophagus. J Gastroenterol Hepatol. 22:2222–2227. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kolodziejczyk J and Ponczek MB: The role
of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs)
in tumor progression. Contemp Oncol (Pozn). 17:113–119.
2013.PubMed/NCBI
|
|
46
|
Liu Q, Fang S, Liang S, Lv J, Wang G, Tang
R, Ji X, Zhao T, Li J, Xu L, et al: The prognostic role of a
combined fibrinogen and inflammation-based index in patients with
metastatic breast cancer. Transl Cancer Res. 9:7065–7078. 2020.
View Article : Google Scholar : PubMed/NCBI
|
